logo-loader
viewOncimmune

Oncimmune Holdings signs master service agreement with California-based immunotherapy specialist

It will profile patient plasma samples and assess treatment candidates discovered using the Augmenta's SingleCyte and DeepGrid platforms

Oncimmune -

Oncimmune Holdings PLC (AIM: ONC) said it has signed a master service agreement with California-based Augmenta Bioworks to profile patient plasma samples and assess treatment candidates discovered using the latter’s SingleCyte and DeepGrid platforms.

The first project will deploy SeroTag, Oncimmune's oncology technology, which will be used to identify potential therapeutic antibodies that bind to human antigens found in cancer patients.

The analysis will also provide insight into clinical efficacy as well as “off-target and non-specific binding” as an indicator, for example, for adverse events, Oncimmune said.

Under the deal, there is the option to substantially increase the number of samples analysed and to run these samples over the UK company’s infectious disease panel. Last month Oncimmune said its NavigAID panel would be used in a major coronavirus (COVID-19) initiative to assess disease severity and therapeutic response.

Oncimmune's partner Augmenta, meanwhile, works with leading pharma and biotech companies as well as research institutions “to discover new therapies by identifying the human immune system's protective response to diseases”.

"We are delighted to be partnering with such a progressive and respected organisation as Augmenta on this important programme,” said chief executive Adam Hill in a statement.

“Oncimmune's proven SeroTag proprietary biomarker discovery engine is ideally suited to this project. We are also excited about the prospect of, once again, utilising our infectious diseases panel to help support the fight against COVID-19."

Quick facts: Oncimmune

Price: 162.5 GBX

AIM:ONC
Market: AIM
Market Cap: £103.25 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Oncimmune Holdings' collaborate with US based Augmenta Bioworks to profile...

Oncimmune Holdings PLC's (LON:ONC) Adam Hill tells Proactive London about their master service agreement with California-based immunotherapy specialist Augmenta Bioworks. This collaboration will profile patient plasma samples and assess treatment candidates discovered using the latter’s...

2 weeks, 3 days ago

2 min read